Abstract
BACKGROUND Installation of technologies to remove or deactivate respiratory pathogens from indoor air is a plausible non-pharmaceutical disease control strategy.
METHODS We undertook a systematic review of observational and experimental studies, published 1970-2022, to synthesise evidence about the effectiveness of suitable indoor air treatment technologies to prevent respiratory or gastrointestinal infections. We searched for data about infection and symptom outcomes for persons who spent minimum 20 hours/week in shared indoor spaces subjected to air treatment strategies hypothesised to change risk of respiratory or gastrointestinal infections or symptoms.
RESULTS Pooled data suggested no net benefits for symptom severity or symptom presence, in absence of confirmed infection. There was weak evidence that air treatment technologies tended to reduce confirmed infections, but these data evinced strong publication bias.
CONCLUSION Although environmental and surface samples are reduced after air treatment by several air treatment strategies, especially germicidal lights and high efficiency particulate air filtration, robust evidence has yet to emerge to confirm that these technologies are effective in real world settings. Data from several relevant randomised trials have yet to report and will be welcome to the evidence base.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
ICS, IRL, PRH, JB and EJA were funded by the National Institute for Health Research Health Protection Research Unit (NIHR HPRU) in Emergency Preparedness and Response at Kings College London in partnership with the UK Health Security Agency (UKHSA), in collaboration with the University of East Anglia. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, any of our employers, the Department of Health or the UKHSA.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Other email addresses: isabel.swindells{at}icloud.com, Anastasia.Kolyva{at}nnuh.nhs.uk, C.Letley{at}uea.ac.uk, Elizabeth.Archer{at}uea.ac.uk, N.Jones{at}uea.ac.uk, K.Pond{at}surrey.ac.uk, Paul.Hunter{at}uea.ac.uk, I.Lake{at}uea.ac.uk
Data Availability
All data produced in the present work are contained in the manuscript